Core Viewpoint - The "climax needle" concept has led to significant stock price fluctuations in related companies, highlighting the volatility and speculative nature of the medical beauty industry [1][4]. Group 1: Market Reaction - On April 28, after the opening of A-shares, stocks related to the "climax needle" concept experienced a collective decline, with Bawei Co. (837023) dropping over 9%, Demei Chemical (002054.SZ) down more than 7%, and Tianyuan Co. (002386.SZ) falling over 5% [1]. - Prior to the decline, these stocks had surged due to speculation surrounding the "climax needle," with some reaching their daily limit [1]. Group 2: Product Details - The "climax needle" is marketed as an injection of collagen at sensitive points within the female vagina, with prices ranging from thousands to tens of thousands of yuan [1]. - A specific product developed by Yuanxiang Biotechnology is priced at 9,800 yuan per injection and is classified as a "platelet-rich plasma preparation device" (PRP), which is a strictly regulated Class III medical device [3]. Group 3: Medical and Regulatory Insights - PRP technology involves extracting a patient's blood, processing it to concentrate platelets, and utilizing growth factors for tissue repair and regeneration [3]. - While PRP has been increasingly applied in the medical beauty sector, the National Medical Products Administration has not yet issued clear approvals for its use in facial injections, despite existing clinical literature [3][4]. - Experts have criticized the "climax needle" as lacking scientific support and warned of potential risks associated with its use, indicating a need for regulatory scrutiny in the medical beauty industry [1][4].